Blood test may replace scans for lymphoma monitoring
NCT ID NCT06744075
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a blood test that looks for tumor DNA (called ctDNA) can predict if lymphoma will come back after first treatment. Researchers will compare this 'liquid biopsy' to standard PET scans in 108 adults with B-cell or Hodgkin lymphoma. The goal is to see if the blood test is more accurate at forecasting outcomes at 1 and 2 years, which could eventually help doctors decide if patients need more or less treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could make ctDNA clearance a standard way to predict lymphoma progression, helping doctors tailor treatment intensity for each patient.
- What could go wrong
- This is an observational study, not a treatment trial. The blood test may not prove more accurate than current PET scans, and results may not change practice without larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Henri Becquerel
Rouen, 76038, France
-
Hôpital Jacques Monod
Montivilliers, 76290, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells be engineered to fight blood cancer?